Guardant Health

Guardant Health, founded in 2012 by AmirAli Talasaz, has raised $557M across private and public financings, including a $360M Series E in 2017 and later IPO placements. The company develops liquid biopsy technologies, enabling tumor DNA sequencing from blood for precision oncology, therapy selection, and clinical trial matching. Funding supported R&D, clinical validation, commercial scaling, and pharma partnerships. Employing around 1,351 people, Guardant Health accelerates adoption of non-invasive genomic testing. Investors include Lightspeed Venture Partners, Sequoia Capital, SoftBank Vision Fund, OrbiMed, and Khosla Ventures, positioning the company as a leader in oncology diagnostics and liquid biopsy innovation.